Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase III studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat® versus placebo and formoterol over 48 weeks in patients with moderate to very severe chronic obstructive p...

Full description

Bibliographic Details
Main Authors: Koch, Andrea, Pizzichini, Emilio, Hamilton, Alan, Hart, Lorna, Korducki, Lawrence, De Salvo, Maria Cristina, Paggiaro, Pierluigi
Format: Online
Language:English
Published: Dove Medical Press 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094569/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094569/

Similar Items